Citigroup Upgrades Biogen Idec and Elan

Analysts Elise Wang and Andrew Swanson believe the market overreacted Monday to the supsension of marketing for multiple sclerosis drug Tysabri

Citigroup upgrades Biogen Idec (BIIB ) to buy from hold and Elan (ELN ) to hold from sell.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.